RemeGen’s telitacicept met its primary endpoint in a prespecified interim analysis of a Phase 3 trial in biopsy-proven IgA nephropathy with persistent proteinuria. At week 39, patients on once-weekly subcutaneous telitacicept (240 mg) reduced their 24-hour urinary protein-to-creatinine ratio by 58.9% versus 8.8% with placebo, a relative difference of -55.0% (P<0.001), with no unexpected safety signals reported.